MEDIZIN

DOC-CHECK LOGIN

Cost and financing of comprehensive care

 

From Ike Bomer, Kempenhaege, Netherlands

 

Berlin (20. September 2008) – It is difficult to identify what are the real costs of a certain activity “A” in a hospital. In many cases a hospital does not even know exactly what the costs of “A” are and besides that, one often “interchanges” the costs of “A” and the reimbursement that the hospital receives for “A” from the insurance company. There can be big differences between that, for example in those countries, where the accommodation of the hospital is paid apart by the state or where patients themselves have to pay directly a part of the reimbursement.

 

A second problem in determining costs of comprehensive epilepsy care is that there are always more institutes involved in comprehensive care. As it is difficult to determine the real costs of one organization in such a chain of activities, it is still more difficult to determine the total costs of the whole chain!

 

In general comprehensive epilepsy care will be more expensive than non-comprehensive. That is why it is important to avoid comprehensive care in cases which do not request this kind of care. On the other side it is also important that a patient who needs comprehensive care receives this as soon as possible. If one tries to avoid comprehensive care for people who need this, one takes a risk, consisting of ‘’shopping’’, of false decisions, of non-complete information and so on. Sometimes this brings very bad implications for the patients and at the end very high, often avoidable costs.

 

So the finance system should stimulate the right choice: comprehensive care or not.

Of course the costs of a product or a service always have to be compared with the benefits of it.

Comprehensive epilepsy care may cost a lot, but the positive effects of it – not only in terms of quality of life but also in pure financial terms can be so big, that in many cases it is far more profitable than non-comprehensive care.

 

There is an important restriction: comprehensive epilepsy care is only useful if the quality is guaranteed. Bad comprehensive care causes a lot of misery for the patient and a lot of unnecessary costs.

 

So the message is: comprehensive epilepsy care is more expensive than non-comprehensive. So be critical in the decision to refer to it. But if it is necessary there is a good chance for a huge benefit! Next you have to be critical in choosing a partner for comprehensive epilepsy care for reasons of quality.

 

The West-European Epilepsy Centres in general offer comprehensive care of good quality. The costs of their care usually are more explicit and far lower than in the case of comprehensive care by a chain of different organizations.

 


 

Source: 8th European Congress on Epiteptology, Satellite Symposium: “Comprehensive Care of Epilepsy in Europe”, Berlin, 20. September 2008 (Medizin und PR Kommunikation).

MEDICAL NEWS

Perinatal patients, nurses explain how hospital pandemic policies failed them
Johns Hopkins Medicine expert creates comprehensive guide to new diabetes…
An amyloid link between Parkinson’s disease and melanoma
Ultrasensitive, rapid diagnostic detects Ebola earlier than gold standard test
Paranoia therapy app SlowMo helps people ‘slow down’ and manage…

SCHMERZ PAINCARE

Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern
Wenn Schmerzen nach einer OP chronisch werden
Deutscher Schmerz- und Palliativtag 2021 – ONLINE: Schmerzmediziner, Politiker und…
Deutscher Schmerz- und Palliativtag 2021 – ONLINE: COVID-19-Pandemie belastet Schmerzpatienten…

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ meldet…
Typ-2-Diabetes: Vorteil mit Toujeo® in der Einstellphase – Geringeres Hypoglykämierisiko…
Kinder und Jugendliche mit Typ-1-Diabetes gehören nicht zur Risikogruppe und…
Neue Studie will Entstehung von Typ-1-Diabetes bei Kindern verhindern
Toujeo®: Ein Beitrag zu mehr Sicherheit für Menschen mit Typ-1-Diabetes

ERNÄHRUNG

DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…

ONKOLOGIE

Leberkrebs: Bei welchen Patienten wirkt die Immuntherapie?
Konferenzbericht vom virtuellen Münchener Fachpresse-Workshop Supportive Therapie in der Onkologie
Wie neuartige Erreger die Entstehung von Darmkrebs verursachen können
Onkologische Pflegekräfte entwickeln Hörspiel für Kinder: Abenteuer mit Alfons
Krebsüberleben hängt von der Adresse ab

MULTIPLE SKLEROSE

Multiple Sklerose: Salzkonsum reguliert Autoimmunerkrankung
Erste tierexperimentelle Daten zur mRNA-Impfung gegen Multiple Sklerose
Multiple Sklerose: Immuntherapie erhöht nicht das Risiko für schweren COVID-19-Verlauf
Empfehlung zur Corona-Impfung bei Multipler Sklerose (MS)
Fallstudie: Beeinflusst SARS-CoV-2 Infektion die Multiple Sklerose?

PARKINSON

Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung
Neuer Bewegungsratgeber unterstützt Menschen mit M. Parkinson durch Yoga
Covid-19-Prävention: besondere Vorsicht bei Patienten mit der Parkinson-Krankheit
Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…